New antibody shot study aims to help Immune-Compromised patients

NCT ID NCT07076446

Ongoing Disease control Sponsor: CSL Behring Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated May 20, 2026 · Updated 17 times

Summary

This study tests a medicine called IgPro20, which is given as a shot under the skin, in adults with primary immunodeficiency (PID) who have never received antibody therapy before. The goal is to see how the body processes the drug and whether it is safe. Only 8 people will take part, and they must be 18 or older with a confirmed PID diagnosis and low antibody levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Allergy & Clinical Immunology

Pittsburgh, Pennsylvania, 15241, United States
Allergy, Asthma and Clinical Research Center

Oklahoma City, Oklahoma, 73120, United States
Immunoe Health Centers

Centennial, Colorado, 80112, United States
Johns Hopkins Bayview Medical Center

Baltimore, Maryland, 21224, United States
Medical Research of Arizona

Scottsdale, Arizona, 85251, United States
Midwest Immunology

Plymouth, Minnesota, 55446, United States
Research Solutions of AZ

Litchfield Park, Arizona, 85340, United States
Washington University

St Louis, Missouri, 63141, United States

Conditions

Explore the condition pages connected to this study.

PRIMARY IMMUNODEFICIENCY